Quetiapine for Bipolar I Disorder
Author Information
Author(s): Hardoy Maria Carolina, Garofalo Alessandra, Mellino Gisa, Tuligi Francesco, Cadeddu Mariangela, Carta Mauro Giovanni
Primary Institution: Center for Epidemiology and Clinical Practice in Mental Health ASL 7 Iglesias, Italy
Hypothesis
To assess the long-term response to add-on quetiapine therapy in patients with bipolar I disorder who were not adequately responding to standard medications.
Conclusion
Quetiapine treatment significantly reduced relapse rates of manic and depressive episodes in patients with bipolar I disorder.
Supporting Evidence
- The annual relapse rate decreased from 2.09 episodes to 0.61 episodes after adding quetiapine.
- The relative risk of relapse for all episodes was 3.4 before quetiapine treatment.
- Patients were followed for an average of 15.7 months after starting quetiapine.
Takeaway
This study found that adding quetiapine to treatment helps people with bipolar I disorder have fewer mood episodes.
Methodology
Patients with bipolar I disorder inadequately responsive to ongoing medications were observed before and after receiving quetiapine.
Potential Biases
Potential bias due to the open-label design and lack of randomization.
Limitations
The study was open-label and lacked a control group.
Participant Demographics
61 patients, 41% male and 59% female, aged 18-68 years.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI 2.1–5.5
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website